1. Gerweck LE, Kozin SV. Relative biological effectiveness of proton beams in
clinical therapy. Radiother Oncol. 1999;50:135–42.
2. Paganetti H, Niemierko A, Ancukiewicz M, Gerweck LE, Goitein M, Loeffler JS,
et al. Relative biological effectiveness (RBE) values for proton beam therapy.
Int J Radiat Oncol Biol Phys. 2002;53:407–21.
3. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical
practice: current clinical evidence. J Clin Oncol. 2007;25:965–70.
4. Demizu Y, Jin D, Sulaiman NS, Nagano F, Terashima K, Tokumaru S, et al. Particle therapy using protons or Carbon ions for Unresectable or incompletely
resected bone and soft tissue sarcomas of the Pelvis. Int J Radiat Oncol Biol
Phys. 2017;98:367–74.
5. Iwata H, Murakami M, Demizu Y, Miyawaki D, Terashima K, Niwa Y, et al. Highdose proton therapy and carbon-ion therapy for stage I nonsmall cell Lung
cancer. Cancer. 2010;116:2476–85.
6. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier
ion beams. J Clin Oncol. 2007;25:953–64.
7. Gaito S, Hwang EJ, France A, Aznar MC, Burnet N, Crellin A, et al. Outcomes
of patients treated in the UK Proton Overseas Programme: Central Nervous
System Group. Clin Oncol (R Coll Radiol). 2023;35:283–91.
8. Hwang E, Gaito S, France A, Crellin AM, Thwaites DI, Ahern V, et al. Outcomes
of patients treated in the UK Proton Overseas Programme: non-central
nervous System Group. Clin Oncol (R Coll Radiol). 2023;35:292–300.
24. 25. 26. 27. 28. 29. 30. 31. Ishikawa H, Tsuji H, Kamada T, Hirasawa N, Yanagi T, Mizoe JE, et al. Risk factors
of late rectal bleeding after carbon ion therapy for Prostate cancer. Int J
Radiat Oncol Biol Phys. 2006;66:1084–91.
Komatsu S, Murakami M, Fukumoto T, Hori Y, Hishikawa Y, Ku Y. Risk factors
for survival and local recurrence after particle radiotherapy for single small
hepatocellular carcinoma. Br J Surg. 2011;98:558–64.
Fukumoto T, Komatsu S, Hori Y, Murakami M, Hishikawa Y, Ku Y. Particle beam
radiotherapy with a surgical spacer placement for advanced abdominal
leiomyosarcoma results in a significant clinical benefit. J Surg Oncol.
2010;101:97–9.
Hashimoto Y, Komatsu S, Terashima K, Tsugawa D, Yanagimoto H, Suga M,
et al. Space-making particle therapy for Unresectable Hilar Cholangiocarcinoma. Dig Surg. 2022;39:99–108.
Komatsu S, Demizu Y, Sulaiman NS, Terashima K, Suga M, Kido M, et al. Spacemaking particle therapy for sarcomas derived from the abdominopelvic
region. Radiother Oncol. 2020;146:194–9.
Komatsu S, Hori Y, Fukumoto T, Murakami M, Hishikawa Y, Ku Y. Surgical
spacer placement and proton radiotherapy for unresectable hepatocellular
carcinoma. World J Gastroenterol. 2010;16:1800–3.
Komatsu S, Terashima K, Matsuo Y, Takahashi D, Suga M, Nishimura N, et al.
Validation of combination treatment with surgical spacer placement and
subsequent particle radiotherapy for unresectable hepatocellular carcinoma.
J Surg Oncol. 2019;120:214–22.
Lee D, Komatsu S, Terashima K, Toyama H, Matsuo Y, Takahashi D, et al. Surgical spacer placement for proton radiotherapy in locally advanced pancreatic
body and tail cancers: initial clinical results. Radiat Oncol. 2021;16:3.
Tsugawa D, Komatsu S, Demizu Y, Sulaiman NS, Suga M, Kido M, et al. Spacemaking particle therapy with Surgical Spacer Placement in patients with
Sacral Chordoma. J Am Coll Surg. 2020;230:207–15.
Chung H, Polf J, Badiyan S, Biagioli M, Fernandez D, Latifi K, et al. Rectal dose
to Prostate cancer patients treated with proton therapy with or without
rectal spacer. J Appl Clin Med Phys. 2017;18:32–9.
Rucinski A, Brons S, Richter D, Habl G, Debus J, Bert C, et al. Ion therapy of
Prostate cancer: daily rectal dose reduction by application of spacer gel.
Radiat Oncol. 2015;10:56.
Lorenzo C, Andrea P, Barbara V, Denis P, Rosaria FM, Piero F, et al. Surgical
spacer placement prior carbon ion radiotherapy (CIRT): an effective feasible
strategy to improve the treatment for sacral chordoma. World J Surg Oncol.
2016;14:211.
Yoon SS, Chen YL, Kambadakone A, Schmidt B, DeLaney TF. Surgical placement of biologic mesh spacers prior to external beam radiation for retroperitoneal and pelvic tumors. Pract Radiat Oncol. 2013;3:199–208.
Minohara S, Kanai T, Endo M, Noda K, Kanazawa M. Respiratory gated
irradiation system for heavy-ion radiotherapy. Int J Radiat Oncol Biol Phys.
2000;47:1097–103.
Aibe N, Demizu Y, Sulaiman NS, Matsuo Y, Mima M, Nagano F, et al. Outcomes
of patients with primary sacral chordoma treated with definitive Proton
Beam Therapy. Int J Radiat Oncol Biol Phys. 2018;100:972–9.
Takagi M, Demizu Y, Terashima K, Fujii O, Jin D, Niwa Y, et al. Long-term outcomes in patients treated with proton therapy for localized Prostate cancer.
Cancer Med. 2017;6:2234–43.
Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Niwa Y, et al. The
effectiveness of particle radiotherapy for hepatocellular carcinoma associated
with inferior vena cava Tumor thrombus. J Gastroenterol. 2011;46:913–20.
Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Sasaki R, et al.
Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer. 2011;117:4890–904.
Kagawa K, Murakami M, Hishikawa Y, Abe M, Akagi T, Yanou T, et al. Preclinical
biological assessment of Proton and carbon ion beams at Hyogo Ion Beam
Medical Center. Int J Radiat Oncol Biol Phys. 2002;54:928–38.
Sezeur A, Martella L, Abbou C, Gallot D, Schlienger M, Vibert JF, et al. Small
intestine protection from radiation by means of a removable adapted prosthesis. Am J Surg. 1999;178:22–5.
Waddell BE, Lee RJ, Rodriguez-Bigas MA, Weber TK, Petrelli NJ. Absorbable mesh sling prevents radiation-induced bowel injury during sandwich
chemoradiation for rectal cancer. Arch Surg. 2000;135:1212–7.
Alongi F, Rigo M, Figlia V, Cuccia F, Giaj-Levra N, Nicosia L, et al. Rectal spacer
hydrogel in 1.5T MR-guided and daily adapted SBRT for Prostate cancer:
dosimetric analysis and preliminary patient-reported outcomes. Br J Radiol.
2021;94:20200848.
Cuccia F, Mazzola R, Nicosia L, Figlia V, Giaj-Levra N, Ricchetti F, et al. Impact
of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction
Fujinaka et al. Radiation Oncology
32. 33. 34. 35. (2023) 18:173
motion during 1.5 T MR-guided stereotactic body radiotherapy. Radiat Oncol.
2020;15:178.
Ogino T, Sekimoto M, Nishimura J, Takemasa I, Mizushima T, Ikeda M, et al.
Intraluminal migration of a spacer with small bowel obstruction: a case
report of rare complication. World J Surg Oncol. 2012;10:30.
Shiba S, Okamoto M, Shibuya K, Okazaki S, Kobayashi D, Miyasaka Y, et al.
Safety and Efficacy of Re-irradiation with Carbon-ion Radiotherapy for Pelvic
recurrence of rectal Cancer after Preoperative Chemoradiotherapy: a retrospective analysis. Vivo. 2022;36:2473–80.
Sasaki R, Demizu Y, Yamashita T, Komatsu S, Akasaka H, Miyawaki D, et al.
First-In-Human phase 1 study of a Nonwoven Fabric Bioabsorbable Spacer
for particle therapy: space-making particle therapy (SMPT). Adv Radiat Oncol.
2019;4:729–37.
Akasaka H, Sasaki R, Miyawaki D, Mukumoto N, Sulaiman NS, Nagata M, et al.
Preclinical evaluation of bioabsorbable polyglycolic acid spacer for particle
therapy. Int J Radiat Oncol Biol Phys. 2014;90:1177–85.
Page 10 of 10
36. Shiba S, Okamoto M, Tashiro M, Ogawa H, Osone K, Yanagawa T, et al. Rectal
dose-sparing effect with bioabsorbable spacer placement in carbon ion
radiotherapy for sacral chordoma: dosimetric comparison of a simulation
study. J Radiat Res. 2021;62:549–55.
37. Yamamoto Y, Hino A, Kurihara H, Kano K, Serizawa I, Katoh H, et al. Transitional
changes of spacer materials used in carbon-ion radiation therapy. Asia Pac J
Clin Oncol. 2022;18:e442–7.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
...
論文の公開元へ
